SIGA Technologies Inc (SIGA) company profile
Close on Nov 17, 2026Market cap $196.15MP/E –Yield 21.98%
About SIGA Technologies
Pharmaceutical Preparations, SIC 2834
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on medical countermeasures against biological threats. Its primary product is TPOXX, an antiviral medication available in oral and intravenous formulations for treating human smallpox disease caused by the variola virus. Outside the United States, oral formulations have also obtained regulatory clearances for smallpox, monkeypox, cowpox, and complications related to smallpox vaccination. The company sells its therapies primarily to governmental public health and defense agencies, including the United States Government through the Strategic National Stockpile and Department of Defense, as well as foreign governments and government-affiliated entities, occasionally utilizing distributor arrangements for international markets.
The company operates without internal manufacturing infrastructure, relying instead on third-party contract manufacturing organizations while maintaining a domestic United States supply chain. SIGA employs 49 full-time workers and conducts commercial operations spanning domestic and multiple international jurisdictions, including North America, Europe, and Asia, with its primary corporate offices located in the United States.
Summary of the business section of SIGA Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SIGA Technologies Inc
- Headquarters
- New York, NY
- Address
- 31 East 62nd Street 10065
- Phone
- (212) 672-9100
- Website
- siga.com
- Employees
- 49, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- SIGA
- Former tickers
- SIGAQ until May 6, 2020
- Exchange
- Nasdaq
- IPO date
- Sep 10, 1997
- Shares outstanding
- 72M, Jul 24, 2026
- Public float
- $302.15M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1010086
- CUSIP
- 826917106
- ISIN
- US8269171067
- FIGI
- BBG000BKXWV1
- Share class FIGI
- BBG001S80PZ5
- EIN
- 13-3864870
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Diem Nguyen | Chief Executive Officer, Director | 185,796 |
| Larry R. Miller | General Counsel | 51,912 |
| Dennis E. Hruby | EVP & Chief Scientific Officer | 202,492 |
| Daniel J. Luckshire | Executive VP & CFO | 280,493 |
| Julian Nemirovsky | Director | 80,989 |
| Gary J. Nabel | Director | 73,754 |
| Holly L. Phillips | Director | 80,989 |
| Harold Eugene Ford Jr. | Director | 54,773 |
| Joseph W. Marshall III | Director | 246,523 |
| John M. Keane | Director | 24,116 |
| Jaymie A. Durnan | Director | 88,754 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.24M | $3.74M | $1.56M | $116 | $120 |
| FY2024 | $4.59M | $5.64M | $1.41M | $104 | $91 |
| FY2023 | $1.83M | $1.83M | $1.40M | $88 | $92 |
| FY2022 | $1.74M | $1.74M | $993.87K | $107 | $89 |
| FY2021 | $1.69M | $1.69M | $1.29M | $103 | $99 |
| FY2020 | $1.64M | $1.64M | $1.28M | $152 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Diem Nguyen Chief Executive Officer and Director | $927.00K | $463.50K | $1.85M | – | $3.24M | -27% |
| Daniel J. Luckshire Executive Vice President and Chief Financial Officer | $752.25K | $564.19K | $250.78K | – | $1.57M | +7% |
| Dennis E. Hruby Executive Vice President and Chief Scientific Officer | $748.53K | $561.40K | $249.51K | – | $1.56M | +7% |
| Larry Miller General Counsel and Corporate Secretary | $695.25K | $347.63K | $463.50K | $32.61K | $1.54M | -30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 13, 2026, we had 49 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?